Back to Research

Organization profile

Anaveon AG

Anaveon AG is a clinical-stage immuno-oncology company that develops engineered cytokines to therapeutically enhance the immune system's response to tumors. The company's lead programs focus on selective Interleukin-2 (IL-2) agonists designed to expand tumor-fighting effector cells while avoiding the expansion of immunosuppressive regulatory T cells.

Basel, SwitzerlandFounded 2017

Overview

1. Executive Summary (Confidence: High)

Anaveon AG is a significant player in the longevity and immuno-oncology space, specializing in the engineering of interleukin-2 (IL-2) to overcome the historic toxicity and selectivity issues of first-generation treatments. Founded as a spin-off from the University of Zurich and headquartered in Basel, the organization is backed by blue-chip investors including Syncona and the Novartis Venture Fund. While its initial lead candidate, ANV419, successfully demonstrated safety and selective expansion of CD8+ and NK cells in Phase 1/2 trials, the company has strategically shifted its focus toward its next-generation "cis-signaling" molecule, ANV600. ANV600 is designed to target IL-2 specifically to tumor-specific T cells by anchoring to PD-1, and is currently being evaluated in the "EXPAND-1" Phase 1/2 trial in combination with pembrolizumab (Keytruda) under a partnership with MSD.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.